Our top pick for
vTv Therapeutics Inc is a biotechnology business based in the US. vTv Therapeutics shares (VTVT) are listed on the NASDAQ and all prices are listed in US Dollars. vTv Therapeutics employs 25 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.47|
|52-week range||$1.46 - $3.59|
|50-day moving average||$1.70|
|200-day moving average||$2.16|
|Wall St. target price||$6.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.10|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-2.00%|
|1 month (2021-09-21)||-14.04%|
|3 months (2021-07-21)||-32.26%|
|6 months (2021-04-21)||-39.51%|
|1 year (2020-10-21)||-10.37%|
|2 years (2019-10-21)||4.26%|
|3 years (2018-10-19)||3.74|
|5 years (2016-10-21)||6.81|
|Revenue TTM||$7.4 million|
|Gross profit TTM||$-4,601,000|
|Return on assets TTM||-38.53%|
|Return on equity TTM||-238.99%|
|Market capitalisation||$122.4 million|
TTM: trailing 12 months
There are currently 2.2 million vTv Therapeutics shares held short by investors – that's known as vTv Therapeutics's "short interest". This figure is 39.3% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting vTv Therapeutics shares can be evaluated.
vTv Therapeutics's "short interest ratio" (SIR) is the quantity of vTv Therapeutics shares currently shorted divided by the average quantity of vTv Therapeutics shares traded daily (recently around 3.4 million). vTv Therapeutics's SIR currently stands at 0.64. In other words for every 100,000 vTv Therapeutics shares traded daily on the market, roughly 640 shares are currently held short.
However vTv Therapeutics's short interest can also be evaluated against the total number of vTv Therapeutics shares, or, against the total number of tradable vTv Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case vTv Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 vTv Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0944% of the tradable shares (for every 100,000 tradable vTv Therapeutics shares, roughly 94 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against vTv Therapeutics.
Find out more about how you can short vTv Therapeutics stock.
We're not expecting vTv Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, vTv Therapeutics's shares have ranged in value from as little as $1.46 up to $3.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while vTv Therapeutics's is -1.6545. This would suggest that vTv Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, vTv Therapeutics has bucked the trend.
vTv Therapeutics Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PDE4 inhibitor; HPP737, a PPAR-delta agonist; and an Nrf2 activator through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.